New biologics facility to be built at MSD Dunboyne
MSD will build a new manufacturing facility at the company’s newly acquired Dunboyne Biologics campus in Co. Meath.
The new facility is expected to create an estimated 140 new jobs by 2025 and will support an innovative new approach to developing and launching MSD’s future biologics medicines. Additionally, the existing MSD Dunboyne Biologics facility expect to hire approximately 100 new employees within the coming year.
Co-locating this new facility beside an existing plant will support greater innovation and collaboration between MSD’s research and manufacturing teams, which will significantly accelerate the time it takes to bring a medicine to market benefiting patients world-wide. Planning and design of the facility will commence immediately, with the aim of completing construction and commencing operations in 2023.
Sanat Chattopadhyay, Executive Vice President & President, Manufacturing Division, MSD, commented: “This is an exciting new direction for MSD and will see our manufacturing and medical research colleagues working collaboratively and flexibly to speed up the process of bringing the medicines of tomorrow to the patients that need them as quickly as possible. By co-locating the new facility alongside our existing operations in Dunboyne, we can accelerate the commercialisation process, reduce lead times significantly and build the ideal environment for developing new technologies and talent.”
Commenting on the announcement An Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar T.D, said “I warmly welcome the announcement by MSD Ireland that it will build a new manufacturing facility at its Dunboyne Biologics campus. This important investment will directly create 140 new jobs by 2025 and a further 100 will also be hired in the existing facility on the site over the coming year. These 240 new jobs are a really welcome boost for Meath I wish MSD the very best with the project.”
CEO of IDA Ireland, Martin Shanahan said: “Today’s announcement by MSD is proof of the company following through on its intention, after the acquisition of the site in September, to further develop its operations there. This expansion positions the Dunboyne Biologics Camp to become an integral part of the company’s global operations as it prepares to meet increasing global demand for its products. It shows real commitment to, and confidence in Co. Meath and the wider Mid-East Region, and in Ireland. MSD is a significant and valued investor in Ireland since it first established operations here more than 50 years ago. The 240 additional jobs being created at the Dunboyne Biologics Camp will be a substantial boost to the regional economy. I wish the company continued success.”
Eva Gallagher, Plant Manager, MSD Dunboyne Biologics stated “This expansion will offer a truly unique approach to manufacturing, ensuring that Dunboyne Biologics is at the cutting edge of pharmaceutical manufacturing and offering our team incredible career opportunities and experience. It’s a really exciting time for our site but also our MSD Ireland colleagues, positioning us at the very heart of MSD’s future.”
MSD Ireland is one of the country’s leading healthcare companies, having first established here over 50 years ago. MSD currently employs approximately 2,700 employees, across our six sites in Ballydine, Co Tipperary, Brinny, Co Cork, Carlow, Dunboyne, Co. Meath and Dublin and, in addition, operate substantial Human Health and Animal Health businesses. MSD’s Irish sites manufacture approximately half of MSD’s top twenty products, saving and enhancing lives in over sixty countries around the world. Further information on MSD Ireland and current job vacancies can be accessed at www.msd.ie.